Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer
Conclusions:
In this population-based cohort, first-line FOLFIRINOX was the strongest predictor of second-line chemotherapy. Duration of therapy remains short and novel treatments are urgently needed.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Pancreas | Pancreatic Cancer | UK Health